Print this page
melanoma
-
A Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy.
Protocol: 082210Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
A Randomized Trial of High-Risk Metachronous OligometastatIc Prostate Cancer with High-Risk Mutations Treated with Metastasis Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS).
Protocol: 082405Principal Investigator:
- Matthew Deek
Applicable Disease Sites: Prostate -
A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer.
Protocol: 082501Principal Investigator:
- Saum Ghodoussipour
Applicable Disease Sites: Urinary Bladder -
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLAA*02:01-Positive Participants with Previously Treated Advanced Melanoma.
Protocol: 092203Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination with Standard of Care Ipilimumab and Nivolumab in Patients with Advanced Melanoma.
Protocol: 092302Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 2 and Phase 3 Peri-Operative trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma.
Protocol: 092303Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2).
Protocol: 092401Principal Investigator:
- Vadim Koshenkov
Applicable Disease Sites: Soft Tissue -
A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma.
Protocol: 092402Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Other Female Genital
Other Male Genital -
Understanding Sun Protection and Skin Examination Practices Among Hispanics.
Protocol: 132111Principal Investigator:
- Carolyn J Heckman
Applicable Disease Sites: Melanoma, Skin -
A Digital Intervention to Improve Skin Self-Examination Among Melanoma Survivors.
Protocol: 132202Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Melanoma, Skin -
Developing and Testing a Mobile Health Intervention to Promote Sun Protection Behaviors and Skin Examination Among Hispanics.
Protocol: 132206Principal Investigator:
- Zhaomeng Niu
Applicable Disease Sites: Other Skin -
Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases.
Protocol: 142403Applicable Disease Sites: Brain and Nervous System
-
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients with Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma.
Protocol: 142502Principal Investigator:
- Morana Vojnic
Applicable Disease Sites: Brain and Nervous System -
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation.
Protocol: 192301Principal Investigator:
- Patrick Boland
Applicable Disease Sites: Any Site
- 1
- 2